Since the clinical steady-state Cmax concentration is higher than their IC50, these TKI agents can make patients with a high incidence of hyperbilirubinemia by effectively inhibiting UGT1A1 (218, 219). This evidence concerns the gene UGT1A1 and Hyperbilirubinemia.